Get the Stockscreener App
0.5215
6.71%
-0.0375
After Hours:
.52
-0.0015
-0.29%
Lexaria Bioscience Corp stock is traded at $0.5215, with a volume of 112.16K.
It is down -6.71% in the last 24 hours and down -1.60% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$0.559
Open:
$0.5501
24h Volume:
112.16K
Relative Volume:
1.05
Market Cap:
$12.93M
Revenue:
$368.00K
Net Income/Loss:
$-9.54M
P/E Ratio:
-1.0892
EPS:
-0.4788
Net Cash Flow:
$-9.47M
1W Performance:
-13.08%
1M Performance:
-1.60%
6M Performance:
-32.96%
1Y Performance:
-46.68%
1-Day Range:
$0.5208
$0.5501
1-Week Range:
$0.5208
$0.591
52-Week Range:
$0.46
$1.55
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.5215 | 13.86M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria Bioscience Corp (LEXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexaria Bioscience Corp (LEXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LEXX|Lexaria Bioscience Corp|Price:0.559|Chg%:-0.011 - TradingKey
Enterprise value to revenue forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Institutional Confidence - TradingKey
Price to book forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp. 10-Q Q3 2026: Financial Results, NASDAQ Listing, and Key Highlights - Minichart
Lexaria Bioscience narrows Q3 loss to $(0.08) per share - scanx.trade
LEXARIA BIOSCIENCE ($LEXX) Releases Q3 2026 Earnings - Quiver Quantitative
Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary - TradingView
Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid - Stock Titan
Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026 - marketscreener.com
Lexaria Bioscience Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Lexaria reports pharmaceutical partnership discussions at BIO - Investing.com
Lexaria reports pharmaceutical partnership discussions at BIO By Investing.com - Investing.com Nigeria
Lexaria Updates Business Development - Investing News Network
Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows - Stock Titan
LEXXLexaria Bioscience Corp Forecast, Target Price - Finviz
Lexaria Bioscience Corp. Actuals & Estimates (NASDAQ:LEXX) - TradingView
Lexaria Begins Dosing in Human Study Evaluating Oral Semaglutide Formulations Against Wegovy - citybuzz -
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule - Investing News Network
Lexaria starts 5-week human GLP-1 study using tablet and capsule forms - Stock Titan
Lexaria begins GLP-1 study dosing evaluating DehydraTECH-semaglutide - scanx.trade
Lexaria Bioscience (LEXX) Advances in Animal Study #1 on Formula - GuruFocus
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule - Investing News Network
Lexaria starts animal GLP-1 study, adds Australian patent - Stock Titan
Lexaria begins dosing in GLP-1 study, receives patent - scanx.trade
Lexaria Bioscience Corp (LEXXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Corp. Financial Disclosures & SEC Filings - TradingView
Lexaria Bioscience Corp (LEXXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexaria Bioscience Corp (LEXXW) Institutional Confidence - TradingKey
Lexaria Bioscience Corp (LEXX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexaria Bioscience Corp (LEXXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Corp (LEXX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexaria Bioscience Corp (LEXX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexaria Bioscience (LEXX) Advances Drug Delivery Technology - GuruFocus
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand - Investing News Network
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand - Investing News Network
Lexaria says GLP-1 drugs are moving into more diseases and markets - Stock Titan
Lexaria Bioscience Corp (LEXXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexaria Bioscience Corp (LEXXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LEXX: Animal & Human GLP-1 Studies Continue - Yahoo Finance
Lexaria Bioscience (LEXX) Completes Dosing in Key Animal Study - GuruFocus
Lexaria completes dosing study on next-generation GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria completes dosing study on next-generation GLP-1 drugs - Investing.com
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):